JP2017513894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513894A5 JP2017513894A5 JP2016564111A JP2016564111A JP2017513894A5 JP 2017513894 A5 JP2017513894 A5 JP 2017513894A5 JP 2016564111 A JP2016564111 A JP 2016564111A JP 2016564111 A JP2016564111 A JP 2016564111A JP 2017513894 A5 JP2017513894 A5 JP 2017513894A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- optionally substituted
- halogen atom
- alkyl group
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 29
- 125000005843 halogen group Chemical group 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 16
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 15
- 125000002950 monocyclic group Chemical group 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- WFSARWQASFQZMG-VXKWHMMOSA-N 4-fluoro-2-[(3S,4S)-4-hydroxyoxan-3-yl]-5-methyl-6-[(4-pyrazol-1-ylphenyl)methyl]-3H-isoindol-1-one Chemical compound FC1=C2CN(C(C2=CC(=C1C)CC1=CC=C(C=C1)N1N=CC=C1)=O)[C@H]1COCC[C@@H]1O WFSARWQASFQZMG-VXKWHMMOSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 claims 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 claims 1
- PQTDWVGBNKIBKC-VXKWHMMOSA-N O[C@@H]1[C@H](CCCC1)N1C(C2=CC(=C(C(=C2C1)C)C)CC=1C=NC(=CC1)C)=O Chemical compound O[C@@H]1[C@H](CCCC1)N1C(C2=CC(=C(C(=C2C1)C)C)CC=1C=NC(=CC1)C)=O PQTDWVGBNKIBKC-VXKWHMMOSA-N 0.000 claims 1
- TYTRQXGARQKALD-VXKWHMMOSA-N O[C@@H]1[C@H](COCC1)N1C(C2=CC(=C(C(=C2C1)C)C)CC1=CC=C(C=C1)OC)=O Chemical compound O[C@@H]1[C@H](COCC1)N1C(C2=CC(=C(C(=C2C1)C)C)CC1=CC=C(C=C1)OC)=O TYTRQXGARQKALD-VXKWHMMOSA-N 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 230000001713 cholinergic effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229940126027 positive allosteric modulator Drugs 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 102000017927 CHRM1 Human genes 0.000 description 1
- 101150073075 Chrm1 gene Proteins 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014089585 | 2014-04-23 | ||
| JP2014089585 | 2014-04-23 | ||
| PCT/JP2015/062912 WO2015163485A1 (en) | 2014-04-23 | 2015-04-22 | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513894A JP2017513894A (ja) | 2017-06-01 |
| JP2017513894A5 true JP2017513894A5 (OSRAM) | 2018-05-24 |
| JP6517239B2 JP6517239B2 (ja) | 2019-05-22 |
Family
ID=53276227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564111A Active JP6517239B2 (ja) | 2014-04-23 | 2015-04-22 | アルツハイマー病治療のためのコリン作動性ムスカリンｍ１受容体ポジティブアロステリックモジュレーター活性としてのイソインドリン−１−オン誘導体 |
Country Status (36)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI719464B (zh) | 2013-03-15 | 2021-02-21 | 美商英塞特控股公司 | 作為bet蛋白抑制劑之三環雜環 |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| PL3134386T3 (pl) * | 2014-04-23 | 2020-11-16 | Takeda Pharmaceutical Company Limited | Pochodne izoindolin-1-onu jako dodatnia aktywność allosterycznego modulatora cholinergicznego receptora muskarynowego m1 do leczenia choroby alzheimera |
| KR20240134245A (ko) | 2014-04-23 | 2024-09-06 | 인사이트 홀딩스 코포레이션 | BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온 |
| EP3144308B1 (en) | 2014-05-16 | 2020-06-24 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| JP6571077B2 (ja) | 2014-06-13 | 2019-09-04 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| TN2017000508A1 (en) | 2015-06-26 | 2019-04-12 | Takeda Pharmaceuticals Co | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| US20170121347A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| US10548877B2 (en) | 2016-03-11 | 2020-02-04 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| EP4234554A3 (en) | 2016-06-20 | 2023-12-27 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| WO2018005249A1 (en) * | 2016-06-28 | 2018-01-04 | Merck Sharp & Dohme Corp. | Benzoisoquinolinone m1 receptor positive allosteric modulators |
| EP3590936B1 (en) | 2017-02-28 | 2021-09-01 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
| US11560372B2 (en) | 2017-04-18 | 2023-01-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds useful as modulators of acetylcholine receptors |
| US12298319B2 (en) | 2017-05-19 | 2025-05-13 | Takeda Pharmaceutical Company Limited | Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators |
| WO2018226545A1 (en) | 2017-06-09 | 2018-12-13 | Merck Sharp & Dohme Corp. | Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor |
| JP7123042B2 (ja) | 2017-06-20 | 2022-08-22 | 武田薬品工業株式会社 | 複素環化合物 |
| HRP20231236T1 (hr) | 2017-06-20 | 2024-02-16 | Takeda Pharmaceutical Company Limited | Heterociklički spoj i njegova uporaba kao pozitivnog alosteričnog modulatora kolinergičkog muskarinskog m1 receptora |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| JP2020158392A (ja) * | 2017-07-25 | 2020-10-01 | Ａｇｃ株式会社 | フルオロフェノール誘導体の製造方法及び新規なフルオロ化合物 |
| EA039902B1 (ru) * | 2017-11-23 | 2022-03-25 | Сувен Лайф Сайенсиз Лимитед | Замещенные азабициклы в качестве положительных аллостерических модуляторов мускаринового рецептора m1 |
| JP7416537B2 (ja) | 2018-09-28 | 2024-01-17 | 武田薬品工業株式会社 | 複素環化合物 |
| US12162864B2 (en) | 2018-09-28 | 2024-12-10 | Takeda Pharmaceutical Company Limited | Condensed-cyclic compound |
| WO2020067456A1 (ja) | 2018-09-28 | 2020-04-02 | 武田薬品工業株式会社 | 複素環化合物 |
| CN113329679A (zh) * | 2018-12-28 | 2021-08-31 | 卢遂显 | 检测治疗和预防神经发育障碍的方法 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN116234552B (zh) * | 2020-07-29 | 2025-02-25 | (株)倍宝尊 | mGluR5和5-HT2A受体的双重调节剂及其用途 |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| WO2025231255A1 (en) * | 2024-05-01 | 2025-11-06 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4416647Y1 (OSRAM) | 1965-05-26 | 1969-07-18 | ||
| JPS60172704A (ja) | 1984-02-14 | 1985-09-06 | Mitsuwa Seiki Co Ltd | 流体アクチユエ−タの制御方法 |
| JP2699511B2 (ja) * | 1988-01-29 | 1998-01-19 | 武田薬品工業株式会社 | 置換アミン類 |
| US5538983A (en) | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| JPH06220044A (ja) * | 1991-12-25 | 1994-08-09 | Mitsubishi Kasei Corp | ベンズアミド誘導体 |
| TW219935B (OSRAM) | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
| GB9409150D0 (en) | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| JP2992677B2 (ja) | 1995-06-05 | 1999-12-20 | 武田薬品工業株式会社 | 骨形成促進医薬組成物 |
| AU5716898A (en) | 1997-01-08 | 1998-08-03 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| EP1316203A2 (en) | 2000-06-30 | 2003-06-04 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| CA2442717A1 (en) | 2001-03-15 | 2002-09-26 | Saegis Pharmaceuticals, Inc. | Methods for restoring cognitive function following systemic stress |
| WO2002081446A1 (en) | 2001-04-06 | 2002-10-17 | Daewoong Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof |
| WO2002081447A1 (en) | 2001-04-06 | 2002-10-17 | Daewoong Pharmaceutical Co., Ltd. | 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof |
| US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| DE10137163A1 (de) * | 2001-07-30 | 2003-02-13 | Bayer Ag | Substituierte Isoindole und ihre Verwendung |
| US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
| EP1596867A4 (en) | 2003-02-19 | 2006-03-22 | Merck & Co Inc | TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR |
| JP2006521399A (ja) | 2003-03-28 | 2006-09-21 | アカディア ファーマシューティカルズ，インコーポレーテッド | 疼痛管理用ムスカリンｍ１受容体アゴニスト |
| US20040266659A1 (en) | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| JP2008537961A (ja) | 2005-04-15 | 2008-10-02 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | Ｇｐｃｒモジュレーター |
| US7868008B2 (en) | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| WO2007044937A2 (en) | 2005-10-13 | 2007-04-19 | President And Fellows Of Harvard College | Compositions and methods to modulate memory |
| GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| TW200806625A (en) | 2006-05-26 | 2008-02-01 | Astrazeneca Ab | Therapeutic compounds |
| US8143284B2 (en) | 2006-10-05 | 2012-03-27 | Abbott Laboratories | Poly(ADP-ribose)polymerase inhibitors |
| US8618074B2 (en) | 2007-03-15 | 2013-12-31 | Board Of Regents Of The University Of Texas System | GPCR enhanced neuroprotection to treat brain injury |
| WO2009039461A2 (en) | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| SI2200610T1 (en) | 2007-09-21 | 2018-06-29 | Acadia Pharmaceuticals Inc. | Co-administration of pimavanserin with other agents |
| WO2009039635A1 (en) * | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| CA2700841A1 (en) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| WO2010042603A1 (en) | 2008-10-08 | 2010-04-15 | Cingulate Neuro Therapeutics, Llc | Amyloid and depression |
| WO2010096338A1 (en) | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
| SG174220A1 (en) | 2009-03-05 | 2011-10-28 | Mithridion Inc | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| US8877944B2 (en) | 2009-07-14 | 2014-11-04 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors |
| PL3061821T3 (pl) | 2009-07-22 | 2020-01-31 | PureTech Health LLC | Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| CA2785499C (en) | 2009-12-22 | 2017-05-02 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
| US8314120B2 (en) * | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
| WO2012003147A1 (en) | 2010-07-01 | 2012-01-05 | Merck Sharp & Dohme Corp. | Isoindolone m1 receptor positive allosteric modulators |
| WO2012149524A1 (en) | 2011-04-29 | 2012-11-01 | The University Of Toledo | Muscarinic agonists as enhancers of working memory and cognitive flexibility |
| EP2709451B1 (en) | 2011-05-17 | 2015-12-30 | Merck Sharp & Dohme Corp. | N-linked lactam m1 receptor positive allosteric modulators |
| WO2012170599A1 (en) | 2011-06-10 | 2012-12-13 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| PL2770997T3 (pl) | 2011-10-28 | 2017-05-31 | Vanderbilt University | Podstawione analogi 2-(4-heterocyklilobenzylo)izoindolin-1-onu jako pozytywne allosteryczne modulatory receptora muskarynowego M1 acetylocholiny |
| JP6211509B2 (ja) | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| US9777005B2 (en) | 2012-11-19 | 2017-10-03 | Takeda Pharmaceutical Company Limited | Bicyclic heterocyclic compound containing a substituted pyrrole ring |
| TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| JP6185660B2 (ja) | 2013-09-27 | 2017-08-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | インドール及びインダゾール誘導体 |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| PL3134386T3 (pl) * | 2014-04-23 | 2020-11-16 | Takeda Pharmaceutical Company Limited | Pochodne izoindolin-1-onu jako dodatnia aktywność allosterycznego modulatora cholinergicznego receptora muskarynowego m1 do leczenia choroby alzheimera |
| WO2017044693A1 (en) | 2015-09-11 | 2017-03-16 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| US20200188388A1 (en) | 2016-12-29 | 2020-06-18 | Rvx Therapeutics Ltd. | Methods and compositions for potentiating cns drugs and reducing their side effects |
-
2015
- 2015-04-22 PL PL15726362T patent/PL3134386T3/pl unknown
- 2015-04-22 PE PE2016002118A patent/PE20161400A1/es unknown
- 2015-04-22 CR CR20160544A patent/CR20160544A/es unknown
- 2015-04-22 TN TN2016000455A patent/TN2016000455A1/en unknown
- 2015-04-22 HU HUE15726362A patent/HUE050543T2/hu unknown
- 2015-04-22 SI SI201531316T patent/SI3134386T1/sl unknown
- 2015-04-22 MY MYPI2016703862A patent/MY195742A/en unknown
- 2015-04-22 CA CA2946519A patent/CA2946519C/en active Active
- 2015-04-22 LT LTEP15726362.5T patent/LT3134386T/lt unknown
- 2015-04-22 TW TW104112837A patent/TWI664165B/zh active
- 2015-04-22 UA UAA201611867A patent/UA122391C2/uk unknown
- 2015-04-22 ES ES15726362T patent/ES2811088T3/es active Active
- 2015-04-22 KR KR1020167032435A patent/KR102349237B1/ko active Active
- 2015-04-22 JP JP2016564111A patent/JP6517239B2/ja active Active
- 2015-04-22 CN CN201580034130.XA patent/CN106536508B/zh active Active
- 2015-04-22 BR BR112016024472-9A patent/BR112016024472B1/pt active IP Right Grant
- 2015-04-22 HR HRP20201171TT patent/HRP20201171T1/hr unknown
- 2015-04-22 SG SG11201608785PA patent/SG11201608785PA/en unknown
- 2015-04-22 MX MX2016013810A patent/MX373274B/es active IP Right Grant
- 2015-04-22 NZ NZ725921A patent/NZ725921A/en unknown
- 2015-04-22 EA EA201692132A patent/EA030373B1/ru not_active IP Right Cessation
- 2015-04-22 US US15/306,012 patent/US9868725B2/en active Active
- 2015-04-22 EP EP15726362.5A patent/EP3134386B1/en active Active
- 2015-04-22 WO PCT/JP2015/062912 patent/WO2015163485A1/en not_active Ceased
- 2015-04-22 RS RS20200816A patent/RS60524B1/sr unknown
- 2015-04-22 PH PH1/2016/502095A patent/PH12016502095B1/en unknown
- 2015-04-22 AU AU2015250610A patent/AU2015250610B2/en active Active
- 2015-04-22 DK DK15726362.5T patent/DK3134386T3/da active
- 2015-04-22 US US14/693,342 patent/US9315458B2/en active Active
- 2015-04-22 UY UY0001036091A patent/UY36091A/es not_active Application Discontinuation
- 2015-04-22 PT PT157263625T patent/PT3134386T/pt unknown
- 2015-04-22 AR ARP150101206A patent/AR100154A1/es active IP Right Grant
-
2016
- 2016-02-02 US US15/013,675 patent/US9518042B2/en active Active
- 2016-02-02 US US15/013,625 patent/US9499516B2/en active Active
- 2016-10-12 US US15/291,769 patent/US9675597B2/en active Active
- 2016-10-19 IL IL24839316A patent/IL248393B/en active IP Right Grant
- 2016-10-19 CL CL2016002661A patent/CL2016002661A1/es unknown
- 2016-10-20 DO DO2016000286A patent/DOP2016000286A/es unknown
- 2016-11-23 EC ECIEPI201690152A patent/ECSP16090152A/es unknown
- 2016-12-22 US US15/388,834 patent/US9655881B2/en active Active
- 2016-12-22 US US15/388,887 patent/US9662316B2/en active Active
-
2017
- 2017-04-14 US US15/488,002 patent/US9775827B2/en active Active
- 2017-05-30 US US15/608,557 patent/US9789083B2/en active Active
- 2017-05-30 US US15/608,565 patent/US9789084B2/en active Active
- 2017-08-24 US US15/685,800 patent/US20180000780A1/en not_active Abandoned
- 2017-12-04 US US15/830,634 patent/US10457670B2/en active Active
-
2018
- 2018-12-04 US US16/209,349 patent/US10865200B2/en active Active
-
2020
- 2020-07-27 CY CY20201100688T patent/CY1123569T1/el unknown
- 2020-09-30 US US17/038,917 patent/US20210009572A1/en not_active Abandoned
-
2022
- 2022-07-25 US US17/872,680 patent/US20220411413A1/en not_active Abandoned
-
2023
- 2023-11-08 US US18/504,741 patent/US20240109874A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017513894A5 (OSRAM) | ||
| HRP20201171T1 (hr) | Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti | |
| JP2017502940A5 (OSRAM) | ||
| JP2015504067A5 (OSRAM) | ||
| JP2017527561A5 (OSRAM) | ||
| JP2017514830A5 (OSRAM) | ||
| JP2008513516A5 (OSRAM) | ||
| JP2020530838A5 (OSRAM) | ||
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| JP2015143283A5 (OSRAM) | ||
| JP2014523851A5 (OSRAM) | ||
| JP2017521407A5 (OSRAM) | ||
| JP2013509392A5 (OSRAM) | ||
| JP2016535772A5 (OSRAM) | ||
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| RU2018114289A (ru) | Бициклические соединения в качестве ингибиторов аутотаксина (atx) | |
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| RU2481330C2 (ru) | Азотсодержащее ароматическое гетероциклическое соединение | |
| JP2011521911A5 (OSRAM) | ||
| RU2015135891A (ru) | Новые производные пиразола | |
| JP2020516671A5 (OSRAM) | ||
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| JP2017533968A5 (OSRAM) | ||
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| JP2016515582A5 (OSRAM) |